Edwards Lifesciences Corporation $EW Stake Lowered by Northwestern Mutual Wealth Management Co.

Northwestern Mutual Wealth Management Co. trimmed its stake in shares of Edwards Lifesciences Corporation (NYSE:EW) by 18.0% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 47,155 shares of the medical research company’s stock after selling 10,362 shares during the quarter. Northwestern Mutual Wealth Management Co.’s holdings in Edwards Lifesciences were worth $4,266,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also made changes to their positions in the stock. Brighton Jones LLC acquired a new stake in Edwards Lifesciences in the fourth quarter worth $266,000. NewEdge Advisors LLC boosted its holdings in shares of Edwards Lifesciences by 8.1% during the second quarter. NewEdge Advisors LLC now owns 35,637 shares of the medical research company’s stock valued at $2,787,000 after acquiring an additional 2,665 shares during the period. Sei Investments Co. boosted its holdings in shares of Edwards Lifesciences by 16.7% during the second quarter. Sei Investments Co. now owns 412,808 shares of the medical research company’s stock valued at $32,285,000 after acquiring an additional 58,988 shares during the period. Squarepoint Ops LLC grew its position in shares of Edwards Lifesciences by 277.7% during the second quarter. Squarepoint Ops LLC now owns 69,263 shares of the medical research company’s stock worth $5,417,000 after acquiring an additional 50,924 shares during the last quarter. Finally, Treasurer of the State of North Carolina increased its holdings in shares of Edwards Lifesciences by 0.4% in the 2nd quarter. Treasurer of the State of North Carolina now owns 268,860 shares of the medical research company’s stock worth $21,028,000 after acquiring an additional 1,065 shares during the period. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Price Performance

Shares of Edwards Lifesciences stock opened at $89.89 on Friday. Edwards Lifesciences Corporation has a 52 week low of $72.30 and a 52 week high of $96.29. The company has a current ratio of 4.52, a quick ratio of 3.77 and a debt-to-equity ratio of 0.06. The stock has a market cap of $51.76 billion, a PE ratio of 51.66, a price-to-earnings-growth ratio of 2.38 and a beta of 0.85. The company’s 50-day moving average price is $89.74 and its two-hundred day moving average price is $85.46.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, topping analysts’ consensus estimates of $0.74 by $0.04. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The firm had revenue of $1.74 billion during the quarter, compared to analysts’ expectations of $1.70 billion. During the same period last year, the firm posted $0.67 earnings per share. The firm’s revenue for the quarter was up 13.6% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. As a group, sell-side analysts anticipate that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on EW. UBS Group began coverage on shares of Edwards Lifesciences in a research report on Tuesday, July 28th. They issued a “buy” rating and a $110.00 price objective on the stock. Evercore reaffirmed an “outperform” rating and set a $100.00 price target on shares of Edwards Lifesciences in a report on Monday, July 6th. Mizuho boosted their price objective on Edwards Lifesciences from $100.00 to $105.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 15th. Piper Sandler reissued an “overweight” rating and issued a $101.00 price objective (up from $100.00) on shares of Edwards Lifesciences in a report on Friday, July 24th. Finally, JPMorgan Chase & Co. raised their target price on Edwards Lifesciences from $100.00 to $105.00 and gave the company an “overweight” rating in a research report on Friday, July 24th. Seventeen investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat, Edwards Lifesciences currently has an average rating of “Moderate Buy” and an average target price of $100.27.

Insider Activity

In other news, SVP Andrew M. Dahl sold 544 shares of the company’s stock in a transaction on Monday, August 31st. The stock was sold at an average price of $91.06, for a total transaction of $49,536.64. Following the completion of the sale, the senior vice president directly owned 14,868 shares of the company’s stock, valued at $1,353,880.08. This represents a 3.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, VP Annette Brüls sold 2,644 shares of Edwards Lifesciences stock in a transaction dated Friday, August 28th. The stock was sold at an average price of $89.98, for a total value of $237,907.12. Following the completion of the transaction, the vice president directly owned 17,984 shares in the company, valued at $1,618,200.32. This represents a 12.82% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 5,045 shares of company stock valued at $457,749 over the last three months. Insiders own 0.31% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.